Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cardinal Health (CAH) reachead $100.83 at the closing of the latest trading day, reflecting a +0.57% change compared to its last close.

Cardinal Health (CAH) Rises But Trails Market: What Investors Should Know

In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.

Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts

In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.

Why the Market Dipped But Cardinal Health (CAH) Gained Today

FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.

Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings

DUBLIN, Ohio , July 23, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2024 on August 14, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2024 on August 14

Benchmark Electronics

Ford Motor Company

Dividend stocks have long been investor favorites. Not only do dividends provide a reliable stream of income but they also increase a portfolio's returns over time.

The 7 Most Undervalued Dividend Stocks to Buy in July 2024

Cardinal Health (CAH) concluded the recent trading session at $96.01, signifying a -0.9% move from its prior day's close.

Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors

Amgen

Fiserv Inc

Globe Life Inc

JPMorgan Chase & Co

Merck

ONEOK

Omnicom Group

Amplify Blackswan Growth & Treasury Core ETF

Innovator Equity Defined Protection ETF - 2 Yr to July 2025

Vulcan Materials

Exxon Mobil

You don't get upset for having homeowner's insurance but your house doesn't burn down. The same principle should apply to investors who insure their stock portfolios against a crash.

‘Crash proof' your portfolio with these 10 stocks and 3 ETFs

Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.

Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes

Cardinal Health is a market leader in healthcare with stable revenue streams and growth opportunities, despite being potentially overvalued. Recent performance shows solid revenue and profit growth, but valuation metrics suggest potential overvaluation compared to sector averages. Growth drivers include expansion in specialty pharmaceuticals, biosimilars market, and emerging healthcare segments, with a focus on operational efficiency and customer value propositions.

Cardinal Health: Growing Into The Valuation

HEICO

NetApp

Simpson Manufacturing

Sysco

This week's increases include Dividend King Sysco Corporation with a 2% increase, extending its 54-year streak. The tables and lists are generated using data from the U.S. Dividend Champions spreadsheet and NASDAQ. I review some companies closer as part of my review process for including them in my own personal portfolio.

5 Upcoming Dividend Increases Including A King

Caterpillar

Deere & Company

Johnson & Johnson

PayPal

Buybacks are in fashion. But at today's valuations, companies could be paying up for their own stock—and that's never a good idea, whether you're a CEO or a retail investor.

5 Cheap Stocks Buying Back Shares at Reasonable Prices

Realty Income Corp

Dividend stocks are not on everyone's radar right now, with Nvidia (NASDAQ: NVDA ) moving past Apple (NASDAQ: AAPL ) to become the second-most-valuable company in the world. And, a host of other artificial intelligence stocks, such as Advanced Micro Devices (NASDAQ: AMD ) lead the pack for mega-cap stocks.

The Dividend Dynasty: 3 Stocks That Will Keep Your Pockets Lined for Years

Cardinal Health, Inc. (NYSE:CAH ) Leerink Partners Healthcare Crossroads Conference May 29, 2024 10:00 AM ET Company Participants Matt Sims - Head, IR Aaron Alt - CFO Conference Call Participants Michael Cherny - Leerink Partners Michael Cherny Great. We'll get started now.

Cardinal Health, Inc. (CAH) Leerink Partners Healthcare Crossroads Conference (Transcript)

Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Investors Heavily Search Cardinal Health, Inc. (CAH): Here is What You Need to Know

Cardinal Health, Inc. (NYSE:CAH ) BofA Securities 2024 Health Care Conference May 14, 2024 11:00 AM ET Company Participants Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Unidentified Analyst CEO, Jason Hollar and CFO, Aaron Alt. First off, thank you both for joining us today.

Cardinal Health, Inc. (CAH) Presents at BofA Securities 2024 Health Care Conference (Transcript)

DUBLIN, Ohio , May 7, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5056 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2024 to shareholders of record at the close of business on July 1, 2024.

Cardinal Health Board of Directors Approves Increase to Quarterly Dividend

McCormick

Altria

Sometimes the best offense is a good defense. In today's market, buying defensive stocks is probably one of the best strategies you can adopt to protect your portfolio's gains.

3 Stocks to Give You Shelter From the Coming Market Crash

Cardinal Health's adjusted diluted EPS surpassed analysts' predictions, reflecting a 20% year-on-year growth. Despite a revenue increase of 9% from the prior year, the company fell short of revenue estimates.

Earnings Beat for Cardinal Health

Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.

Here is What to Know Beyond Why Cardinal Health, Inc. (CAH) is a Trending Stock

Investors are familiar with the phrase "buy the rumor, sell the news." However, Cardinal Health Inc. NYSE: CAH proved that investors can buy and sell the news.

For Cardinal Health, the Proof Will be in Its Performance

The headline numbers for Cardinal (CAH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Cardinal (CAH) Q3 Earnings: A Look at Key Metrics

Cardinal Health, Inc. (NYSE:CAH ) Q3 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Lisa Gill - JP Morgan Michael Cherny - Leerink Partners George Hill - Deutsche Bank Allen Lutz - Bank of America Kevin Caliendo - UBS Eric Percher - Nephron Research Stephanie Davis - Barclays Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Stephen Baxter - Wells Fargo Lucas Romanski - TD Cowen Daniel Grosslight - Citi Operator Hello, and welcome to the Third Quarter Fiscal Year 2024 Cardinal Health Incorporated Earnings Conference Call. My name is George.

Cardinal Health, Inc. (CAH) Q3 2024 Earnings Call Transcript

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

Cardinal Health raised its annual profit forecast on Thursday, betting on strength in its pharmaceutical unit selling costly specialty drugs used to treat complex conditions such as cancer.

News for Cardinal Health Stock (CAH)